| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 04/16/2002 | US6372478 Vaccine vehicles are useful for administration to mammalian hosts for purposes of immunization |
| 04/16/2002 | US6372473 Tissue plasminogen activator-like protease |
| 04/16/2002 | US6372471 Cloning and recombinant production of vespid venom enzymes, such as phospholipase and hyaluronidase, and immunological therapies based thereon |
| 04/16/2002 | US6372462 Cultivating a fungi of the basidiomycetes in a submerged culture on nutrient media, isolating the biomass of edible mushrooms from the culture broth, and drying at a range of 40-45 degrees celsius |
| 04/16/2002 | US6372267 Cocoa solids prepared by heating, pressing, recovering partially defatted cocoa solids which contain cocoa polyphenols including cocoa procyanidins |
| 04/16/2002 | US6372227 Oil in water emulsion containing a sterol and a saponin |
| 04/16/2002 | US6372223 Influenza virus vaccine composition |
| 04/16/2002 | US6372222 Antigenic group B Streptococcus type II and type III polysaccharide fragments having a 2, 5-anhydro-D-mannose terminal structure and conjugate vaccine thereof |
| 04/16/2002 | US6372221 Immunogenic constructs comprising flaviviruses or flavivirus derivatives |
| 04/16/2002 | US6372217 Methods for the treatment of CD7+ viral infection with TXU-7-PAP |
| 04/16/2002 | US6372212 Chitinase materials and methods |
| 04/16/2002 | US6372209 Vaginal lactobacillus medicant |
| 04/16/2002 | US6372207 IFNAR2/IFN complex |
| 04/16/2002 | CA2056503C Stable, solid acetylperoxyborate compounds |
| 04/16/2002 | CA2046607C Inhibiting transformation of cells having elevated purine metabolic enzyme activity |
| 04/16/2002 | CA2009690C Phenylhydrazones, the manufacture thereof and therapeutic and cosmetic compositions prepared therefrom |
| 04/11/2002 | WO2002029413A2 An assay for rhabdovirus inhibitors |
| 04/11/2002 | WO2002029061A2 G-protein coupled receptors |
| 04/11/2002 | WO2002029055A2 Carbohydrate-associated proteins |
| 04/11/2002 | WO2002029036A2 Lipid metabolism enzymes |
| 04/11/2002 | WO2002029035A2 Method to alter sugar moieties |
| 04/11/2002 | WO2002028902A2 Nectin polypeptides, polynucleotides, methods of making and use thereof |
| 04/11/2002 | WO2002028891A2 Listeria inocua, genome and applications |
| 04/11/2002 | WO2002028889A2 Haemophilus influenzae antigens and corresponding dna fragments |
| 04/11/2002 | WO2002028888A2 Mimotope of neisseria meningitides lipooligosaccharide and vaccines containing the same |
| 04/11/2002 | WO2002028887A2 Use of lipopeptides or lipoproteins for treating lung infections and lung tumours |
| 04/11/2002 | WO2002028868A1 Thiazine derivatives |
| 04/11/2002 | WO2002028867A2 Ethers of 7-desmethylrapamycin for use in immunosuppression |
| 04/11/2002 | WO2002028866A2 Hydroxyesters of 7-desmethylrapamycin |
| 04/11/2002 | WO2002028860A2 Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same |
| 04/11/2002 | WO2002028856A1 Pharmaceutically active hydrophilic sulfonamide derivatives as inhibitors of protein junkinases |
| 04/11/2002 | WO2002028847A1 New thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors |
| 04/11/2002 | WO2002028831A1 Inhibitors of prenyl-protein transferase |
| 04/11/2002 | WO2002028829A2 Peptide deformylase inhibitors |
| 04/11/2002 | WO2002028819A1 Naphthylsalicylanilides as antimicrobial and antiinflammatory agents |
| 04/11/2002 | WO2002028440A1 Methods and compositions for modulating t cell activation and uses thereof |
| 04/11/2002 | WO2002028434A2 Use of a ppar delta activator for treating inflammatory conditions |
| 04/11/2002 | WO2002028433A2 Use of a ppar delta activator in the treatment of diseases related to no inhibit ion or tnf inhibition |
| 04/11/2002 | WO2002028428A2 Vaccine composition |
| 04/11/2002 | WO2002028427A2 Pharmaceutical composition for immunisation against aids |
| 04/11/2002 | WO2002028426A1 Split enveloped virus preparation |
| 04/11/2002 | WO2002028424A2 Kyberdrug as autovaccines with immune-regulating effects |
| 04/11/2002 | WO2002028423A1 Stabilisation of plasmid inheritance in bacteria by preventing multimerisation |
| 04/11/2002 | WO2002028422A2 Split enveloped virus preparation for intranasal delivery |
| 04/11/2002 | WO2002028408A2 Compositions and methods for the transport of biologically active agents across cellular barriers |
| 04/11/2002 | WO2002028403A1 Phyllanthus-derived compounds for the prevention and/or treatment of diseases associated with a retrovirus |
| 04/11/2002 | WO2002028390A1 Composition comprising a catalyst for the dismutation of superoxide and use of the composition for preventing and treating hypotension |
| 04/11/2002 | WO2002028384A1 Chloramines as antiviral agents |
| 04/11/2002 | WO2002028377A1 Ihnalation particles incorporating a combination of two or more active ingredients |
| 04/11/2002 | WO2002028371A1 Vaccine composition comprising an immunologically active substance embedded in microparticles consisting of starch with reduced molecular weight |
| 04/11/2002 | WO2002028370A1 Biodegradable microparticles for controlled release administration, with purified amylopectin-based starch of reduced molecular weight |
| 04/11/2002 | WO2002028362A2 Vaccine composition and stabilisation method |
| 04/11/2002 | WO2002028270A2 The treatment of cancer utilizing a cox-2 inhibitor and a hmg-coa reductase inhibitor |
| 04/11/2002 | WO2002012538A3 Nucleic acids and pathogenic e.coli proteins, and their uses |
| 04/11/2002 | WO2002012288A3 Vaccination against host cell-associated herpesviruses |
| 04/11/2002 | WO2002007533A3 Nutritional composition |
| 04/11/2002 | WO2001098328A3 Glycopeptide phosphonate derivatives |
| 04/11/2002 | WO2001090070A3 Caspase inhibitors and uses thereof |
| 04/11/2002 | WO2001089559A3 Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine |
| 04/11/2002 | WO2001087824A3 7-substituted fused ring tetracycline compounds |
| 04/11/2002 | WO2001082963A3 Method of identifying and producing antigen peptides and use thereof as vaccines |
| 04/11/2002 | WO2001076572A3 Use of compatible solutes as substances having free radical scavenging properties |
| 04/11/2002 | WO2001074898A8 Charged compounds comprising a nucleic acid binding moiety and uses therefor |
| 04/11/2002 | WO2001066147A3 Antimicrobial compounds and formulations |
| 04/11/2002 | WO2001066085A3 Micellar pharmaceutical compositions for buccal and pulmonary application |
| 04/11/2002 | WO2001058937A3 Interferon-alpha induced genes |
| 04/11/2002 | WO2001051673A8 Methods and compositions for inhibition of membrane fusion-associated events, including hiv transmission |
| 04/11/2002 | WO2001010906A9 Crystallization and structure determination of staphylococcus aureus elongation factor p |
| 04/11/2002 | WO2000058444A9 Adaptation of virus to vertebrate cells |
| 04/11/2002 | WO2000057907A9 Multivalent dengue virus vaccine |
| 04/11/2002 | WO2000042068A9 Hiv related peptides |
| 04/11/2002 | US20020042435 Cyclic AMP-specific phosphodiesterase inhibitors |
| 04/11/2002 | US20020042421 Antiinflammatory agents |
| 04/11/2002 | US20020042408 Antibiotic compounds |
| 04/11/2002 | US20020042406 Ring opening metathesis of alkenes |
| 04/11/2002 | US20020042397 4-hydroxycinnoline-3-carboxyamides as antiviral agents |
| 04/11/2002 | US20020042394 Antibiotic, images for diagnosis |
| 04/11/2002 | US20020042391 Anticancer agents; viricides |
| 04/11/2002 | US20020042385 Cloning of a novel 7TM receptor AXOR-2 |
| 04/11/2002 | US20020042376 Antiinflammatory agents; autoimmune disease; antiischemic agents |
| 04/11/2002 | US20020042368 Integrin antagonists |
| 04/11/2002 | US20020042365 Vancomycin analogs |
| 04/11/2002 | US20020042123 yybQ |
| 04/11/2002 | US20020042103 Process for the preparation of pseudomonic acid a antibiotic by microbiological method |
| 04/11/2002 | US20020042043 Preparation of a pathogen inactivated solution of red blood cells having reduced immunogenicity |
| 04/11/2002 | US20020041905 Solvent extraction of plant extracts; activation; antituor agents |
| 04/11/2002 | US20020041887 Immune response modifier compounds for treatment of TH2 mediated and related diseases |
| 04/11/2002 | US20020041884 Adenovirus formulations |
| 04/11/2002 | DE10048840A1 Verwendung von Lipopeptiden oder Lipoproteinen zur Behandlung von Lungeninfektionen und -tumoren Use of lipopeptides or lipoproteins in the treatment of lung infections and tumors |
| 04/11/2002 | CA2427842A1 Split enveloped virus preparation for intranasal delivery |
| 04/11/2002 | CA2425269A1 G-protein coupled receptors |
| 04/11/2002 | CA2425266A1 Composition comprising a catalyst for the dismutation of superoxide and use of the composition for preventing and treating hypotension |
| 04/11/2002 | CA2425126A1 Lipid metabolism enzymes |
| 04/11/2002 | CA2424952A1 Listeria inocua, genome and applications |
| 04/11/2002 | CA2424936A1 Vaccine composition comprising an immunologically active substance embedded in microparticles consisting of starch with reduced molecular weight |
| 04/11/2002 | CA2424892A1 Biodegradable microparticles for controlled release administration, with purified amylopectin-based starch of reduced molecular weight |
| 04/11/2002 | CA2424869A1 Phyllanthus-derived compounds for the prevention and/or treatment of diseases associated with a nucleosidic inhibitor-resistant retrovirus or a non-nucleosidic inhibitor-resistantretrovirus |
| 04/11/2002 | CA2424863A1 Vaccine composition and stabilisation method |
| 04/11/2002 | CA2424836A1 Pharmaceutical composition for immunisation against aids |
| 04/11/2002 | CA2424730A1 Compositions and methods for the transport of biologically active agents across cellular barriers |